Posted by Michael Wonder on 07 May 2019
Celgene’s myelodysplastic syndrome treatment gets more insurance benefits
7 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Celgene’s multiple myeloma drug, Revlimid (ingredient: lenalidomide) in treating myelodysplastic syndrome from the start of this month.
The expanded health insurance coverage for the Revlimid lineup (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg) for myelodysplastic syndrome will cover patients with transfusion-dependent anaemia due to low- or intermediate-1–risk myelodysplastic syndromes associated with a deletion 5q cytogenetic (excluding chromosome 7) abnormality.
